RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:180226

Embryonal carcinoma

low confidenceDisorder

Publications

16,957

Trials

6

Interventional, condition-specific

Researchers

1,217

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

carcinoma, embryonal, malignant · embryonal carcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    16,957 matched papers (4,703 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    6 matched on ClinicalTrials.gov (2 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

16,957

16,957 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

16,957 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

4,703 in the last 10 years · low confidence

Phrase hits: 16,953 · MeSH hits: 10

Open Europe PMC search

Who's working on it?

1,217

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Acosta AM6 papers · 2026

    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA.

    Papers in Europe PMC
  2. 02
    Lobo J6 papers · 2026

    Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, Portugal.

    Papers in Europe PMC
  3. 03
    Bremmer F5 papers · 2026

    Institute of Pathology, University Medical Center Göttingen, 37075 Göttingen, Germany.

    Papers in Europe PMC
  4. 04
    Zhang Y5 papers · 2026

    Department of Urology, Anhui Provincial Children's Hospital, Children's Hospital of Fudan University (Affiliated Anhui Branch), No. 39 Wangjing East Road, Hefei, 230000, Anhui Province, People's Republic of China.

    Papers in Europe PMC
  5. 05
    Li X4 papers · 2026

    Department of Abdominal Radiotherapy, Harbin Medical University Cancer Hospital, China.

    Papers in Europe PMC
  6. 06
    Lopes LF4 papers · 2026

    Pediatric Oncology Research Group, Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo 14784400, Brazil.

    Papers in Europe PMC
  7. 07
    Pinto MT4 papers · 2026

    Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo 14784400, Brazil.

    Papers in Europe PMC
  8. 08
    Sarkar T4 papers · 2025

    Department of General, Visceral, Thoracic, and Transplant Surgery, University Hospital Giessen, Giessen, Germany.

    Papers in Europe PMC
  9. 09
    Andrews PW3 papers · 2025

    The Centre for Stem Cell Biology, The School of Biosciences, The University of Sheffield, Western Bank, Sheffield, UK.

    Papers in Europe PMC
  10. 10
    Cardoso IIV3 papers · 2025

    Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo 14784400, Brazil.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

6

interventional trials for this specific condition

6 interventional trials matched this specific condition name; 2 currently recruiting in our sample.

Data as of 27 July 2026

6 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 89th percentile).

low confidence · 89th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

6 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Embryonal carcinoma" OR "carcinoma, embryonal, malignant"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Carcinoma, Embryonal

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Embryonal carcinoma" OR "carcinoma, embryonal, malignant" OR "Carcinoma, Embryonal"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 6 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (16957) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T09:02:05.093Z